Drug Trial Radar · NCT01807221
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Last checked: Nov 20, 2026Latest source record: Jul 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,066
Actual
Start
Jun 17, 2013
Primary completion
Nov 11, 2014
Study completion Dec 9, 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Mar 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compared to eplerenone, another marketed drug approved to treat heart failure.
Conditions
- Heart Failure
Interventions
Finerenone (BAY94-8862)Drug
PlaceboDrug
Inspra (eplerenone)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90Time frame: Baseline and Day 90
Locations
172 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Jacksonville, Florida
Site not named
Macon, Georgia
Site not named
Baltimore, Maryland
Site not named
Detroit, Michigan
Site not named
Detroit, Michigan
Site not named
Newark, New Jersey
Site not named
Fairfield, Ohio
Site not named
Concord, Australia
Site not named
Prahran, Australia
Site not named
Darlinghurst, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Krems, Lower Austria, Austria
Site not named
Graz, Styria, Austria
Site not named
Graz, Styria, Austria
Site not named
Innsbruck, Tyrol, Austria
Site not named
Linz, Upper Austria, Austria
Site not named
Burgas, Bulgaria
Site not named
Pazardzhik, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Québec, Canada
Site not named
Calgary, Alberta, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Saint-Jean-sur-Richelieu, Quebec, Canada
Site not named
Sherbrooke, Quebec, Canada
Site not named
Jindřichův Hradec, Czechia
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.